Diagnostic Medical Systems (XPAR:ALDMS) Research & Development: €0.00 Mil (TTM As of Dec. 2025)


XPAR:ALDMS Diagnostic Medical Systems XPAR:ALDMS
68 GF Score
Price €1.25
GF Value €1.14
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Diagnostic Medical Systems Research & Development?

Diagnostic Medical Systems XPAR:ALDMS -1.57% 68 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates XPAR:ALDMS with a GF Score™ of 68/100 and a GF Value™ of €1.14 (Fairly Valued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Diagnostic Medical Systems's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Diagnostic Medical Systems  (XPAR:ALDMS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Diagnostic Medical Systems Research & Development Related Terms

Diagnostic Medical Systems Research & Development Historical Data

* Premium members only.

The historical data trend for Diagnostic Medical Systems's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Diagnostic Medical Systems Research & Development Chart

Diagnostic Medical Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Diagnostic Medical Systems Semi-Annual Data
Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XPAR:ALDMS
68GF Score
Diagnostic Medical Systems XPAR:ALDMS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Diagnostic Medical Systems Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Diagnostic Medical Systems (XPAR:ALDMS) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Diagnostic Medical Systems and its competitors.
Is Diagnostic Medical Systems' Research & Development too high?
Diagnostic Medical Systems' current Research & Development is €0.00 Mil. Overall, Diagnostic Medical Systems has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Diagnostic Medical Systems' Research & Development compare to ABT and SYK?
Diagnostic Medical Systems' Research & Development of €0.00 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Diagnostic Medical Systems and its competitors. Diagnostic Medical Systems's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostic Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, Diagnostic Medical Systems (XPAR:ALDMS) is currently considered Fairly Valued. The stock's GF Value™ is €1.14, compared to a current price of €1.25 — trading 9.6% above its estimated fair value. The current Research & Development is €0.00 Mil. Diagnostic Medical Systems' overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Diagnostic Medical Systems (XPAR:ALDMS), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Diagnostic Medical Systems (XPAR:ALDMS) Overvalued in 2026?

Based on GuruFocus' analysis, Diagnostic Medical Systems stock appears to be overvalued. The current stock price of €1.25 is trading 9.6% above its estimated GF Value™ of €1.14. GuruFocus considers Diagnostic Medical Systems to be Fairly Valued.

Key valuation signals for XPAR:ALDMS:

  • Research & Development: €0.00 Mil
  • GF Value™: €1.14 vs. price of €1.25 (9.6% above fair value)
  • GF Score™: 68/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALDMS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Diagnostic Medical Systems Business Description

Other Exchanges 0RIA:UKDMS1:Germany
Address 9 Avenue du Canal Philippe, Gallargues le Montueux, FRA, FR-30660
Diagnostic Medical Systems is France's company engaged in the development, design, and production of imaging systems for digital and conventional radiology and osteodensitometry. The group's activity is organized around two sectors: Radiology equipment and osteodensitometers sales: mobile radiology units, floating table tops, operating room mobile amplifiers, ultrasound osteodensitometers (designed to chart the bone micro-architecture) and X ray osteodensitometers (designed to measure bone density), etc. The group also proposes devices distribution and maintenance activities; and the Development of biotechnology solutions: in the fields of arthrosis treatment and regenerative medicine.
68GF Score

Get the complete analysis for XPAR:ALDMS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.25
Price
€1.14
GF Value